1. Home
  2. TENX vs COCH Comparison

TENX vs COCH Comparison

Compare TENX & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$11.75

Market Cap

56.2M

Sector

Health Care

ML Signal

HOLD

Logo Envoy Medical Inc.

COCH

Envoy Medical Inc.

HOLD

Current Price

$0.64

Market Cap

47.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENX
COCH
Founded
1967
1995
Country
United States
United States
Employees
N/A
47
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
56.2M
47.1M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
TENX
COCH
Price
$11.75
$0.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$29.67
$6.00
AVG Volume (30 Days)
605.5K
118.1K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.34
$0.36
52 Week High
$18.38
$1.91

Technical Indicators

Market Signals
Indicator
TENX
COCH
Relative Strength Index (RSI) 37.17 42.60
Support Level $10.83 $0.63
Resistance Level $14.15 $0.73
Average True Range (ATR) 0.95 0.04
MACD -0.28 -0.00
Stochastic Oscillator 7.00 17.62

Price Performance

Historical Comparison
TENX
COCH

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

About COCH Envoy Medical Inc.

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

Share on Social Networks: